| KALL seeks to provide investment results that, before fees and expenses,
track the price performance of the MSCI China All Shares Index. The
index seeks to track the equity market performance of companies based
in China and listed in mainland China, Hong Kong, and the United States. |
FUND BASICS
| Category |
Emerging Market Equities |
| Fund Sponsor |
Krane Fund Advisors LLC |
| Website |
www.kraneshares.com |
| Inception date |
Feb 12, 2015 |
| Assets (mns) |
$9 |
| Currency |
USD |
| Expense ratio |
49 bp |
| Distributions |
Semi-annual |
FUND STRUCTURE
| Regulation |
Open-End Investment Company |
| Custodian |
Brown Brothers Harriman & Co |
| Weighting |
Market Cap |
| Index replication |
Optimized |
| Uses derivatives |
No |
| Options available |
Yes |
CONSTITUENT BREAKDOWN
| No. of constituents |
3 |
| Wgt avg mkt cap (mns) |
$0 |
| Large cap (>$10bn) |
88.7% |
| Mid cap ($2-10bn) |
11.3% |
| Small cap (<$2bn) |
0.0% |
| Developed mkts |
15.5% |
| Emerging mkts |
84.5% |
TOP TEN HOLDINGS
| KANGMEI PHARMA - RIGHTS O |
0.0 % |
Total |
0.0 % |
TOP COUNTRY EXPOSURE
 |
|
0.0 % |
Standardized Annual Returns (thru October 31)
| Year-to-date |
1 year |
5 years |
10 years |
Since Incep. |
| -- |
-- |
-- |
-- |
0.0% |
Market Correlations
| versus... |
Beta |
R-squared |
| S&P500 |
0.48 |
27% |
| MSCI EAFE |
0.89 |
55% |
| MSCI Emg. Mkts. |
1.00 |
72% |
Technical Indicators
| Recent close |
$22.28 |
| 30d moving avg. |
$21.56 |
| Annualized volatility |
29.0% |
| Short interest (ETF) |
0.1% |
| Relative strength (RSI) |
53 |
Liquidity measures
| Avg. volume (thou.) |
0 |
| Turnover |
0.0% |
| Bid/Ask (% of price) |
0.35% |
| ADV underlying (mns) |
$25,946 |
 |
There were no matches found with other funds under coverage. |
Content on this tab for subscribers only**
| |
2020 |
2021 |
2022 |
2023 |
2024 |
2025E |
2026E |
| Sales per share |
** |
** |
** |
** |
** |
** |
** |
| Earnings per share |
** |
** |
** |
** |
** |
** |
** |
Dividends per share  |
** |
** |
** |
** |
** |
** |
** |
| Book value per share |
** |
** |
** |
** |
** |
** |
** |
| Sales per share growth |
|
**% |
**% |
**% |
**% |
**% |
**% |
| EPS growth |
|
**% |
**% |
**% |
**% |
**% |
**% |
| Sales per share growth |
|
**% |
**% |
**% |
**% |
**% |
**% |
| EPS growth |
|
**% |
**% |
**% |
**% |
**% |
**% |
| Long term EPS growth est. |
**% |
|
Debt-to-equity |
**x |
| Asset turnover |
**% |
|
Assets-to-equity |
**x |
Revision activity*
|
| *Six months ago = 100 |
Compound annual growth rates
|
Content on this tab for subscribers only
| |
2024 |
2025E |
2026E |
| Price-to-sales |
** |
** |
** |
| Price-to-earnings |
** |
** |
** |
| Price-to-cash flow |
** |
** |
** |
| Price-to-growth |
** |
** |
** |
| Price-to-book value |
** |
** |
** |
| Yield |
** |
** |
** |
SPECULATIVE |
| Deeply undervalued but risky. A rating of SPECULATIVE is assigned to ETFs with ALTAR Scores in the top quintile (the top 20%) of their category, indicating exceptional appreciation potential. However, often these are narrowly-focused funds or in industries with structural issues, which may also make them very risky. Nonetheless they may still be useful as part of a well-diversified portfolio. |
| Calculation of ALTAR Score™ |
| Avg. Return on Equity |
10.4 |
% |
| Divided by: Fwd. P/BV |
0.8 |
x |
| Less: Expense ratio |
49 |
bp |
| Equals: ALTAR Score |
12.5 |
% |
|
| More information on ALTAR Score™ |
|
|
|
Fundamentals